Funding
Reverion, a company pioneering carbon-negative, reversible power plants, has secured $62 million in Series A funding, including non-dilutive capital. The round, which exceeded expectations, was led by Energy Impact Partners (EIP) and saw backing from Honda and the European Innovation Council Fund (EIC Fund).
Purple Transform, an AI-driven data analytics firm specialising in preventing incidents like theft, trespassing, and antisocial behaviour on railway lines, has secured £4.5m in a funding round led by Mercia Ventures through the Midlands Engine Investment Fund II, with backing from Sure Valley Ventures.
Twin Science & Robotics, a UK-based edtech startup, has secured £1.25 million in a funding round led by Soulmates Ventures, with participation from APY Ventures, existing backers, and notable angel investors. This new investment will fuel the company’s global growth, with a particular focus on expanding its presence in the US.
SOLASTA Bio, a Glasgow-based agri-biotech firm pioneering next-generation green insecticides, has closed an oversubscribed $14 million Series A funding round. The capital injection will accelerate the development of its peptide-based bioinsecticides – innovative, nature-inspired solutions that represent a world-first in the industry.
Recruitment technology company, Willo, has raised £1.8 million in a recent funding round, with significant backing from Peter Bauer, the US-based founder of Mimecast, a global business in email security. Bauer’s £1.5 million investment highlights his confidence in Willo’s potential for significant international growth, driven by its advanced video interview platform.
HeyFlow, a company focused on female reproductive health inclusion in the workplace, has become the first investment client of Aer Venture Studios, the impact-driven SaaS arm of Aer Studios. The £235,000 investment will support the development of HeyFlow’s tech platform and employee insight product, helping the company expand its reach to more enterprise clients.
CardiaTec, a biotech company focused on decoding the biology behind cardiovascular disease, has announced the successful completion of a $6.5 million seed funding round. This capital injection will enable CardiaTec to enhance its platform and advance its proprietary drug targets into the preclinical phase.












